Article
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
European journal of cancer (Oxford, England : 1990) - 1 Sept 2018
Kasper Edwige, Angot Emilie, Colasse Elodie, Nicol Lionel, Sabourin Jean-Christophe, Adriouch Sahil, Lacoume Yann, Charbonnier Camille, Raad Sabine, Frebourg Thierry, Flaman Jean-Michel, Bougeard Gaëlle
Abstract excerpt
INTRODUCTION: Li-Fraumeni syndrome (LFS), due to TP53 germline mutations, is characterised by a remarkably high incidence of multiple primary cancers (MPCs), and the key role of p53 in response to DNA damage questions the contribution of anticancer treatments to MPCs development. MATERIALS AND METHODS: We first evaluated genotoxicity of X-rays and different classes of conventional chemotherapies, thanks to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.